Disease-Free Survival – Talk Bio

Actionable Insights Powered by AI

Tecentriq Demonstrates Survival Benefit in ctDNA-Guided Bladder Cancer Treatment at ESMO 2025

1 week ago talkbio0Tagged adjuvant treatment, atezolizumab, ctDNA-guided therapy, Disease-Free Survival, ESMO, genentech, IMvigor011, Malignant neoplasm of urinary bladder, muscle-invasive bladder cancer, Overall Survival, Roche (company), Signatera, Tecentriq

Tecentriq; atezolizumab; ctDNA-guided therapy; IMvigor011; bladder cancer; muscle-invasive bladder cancer; adjuvant treatment; overall survival; disease-free survival; ESMO 2025; Signatera; Genentech; Roche

AstraZeneca’s Imfinzi Achieves Success in Bladder Cancer Trial, Falls Short in Lung Cancer Study

1 year ago talkbio0Tagged AstraZeneca, Disease-Free Survival, Imfinzi, Malignant neoplasm of lung, Malignant neoplasm of urinary bladder, Phase 3 Clinical Trials

AstraZeneca, Imfinzi, bladder cancer, lung cancer, Phase III trials, disease-free survival